Stoke Therapeutics (STOK) Osake Kurssi

Stoke Therapeutics Inc is primarily active in the biotechnology industry.

The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.

Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.

Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.

Stoke Therapeutics Inc is primarily present in the United States.

Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.

Analyytikot asettavat tällä hetkellä Stoke Therapeutics-osakkeelle keskimääräisen tavoitehinnan 47,33 USD (mediaani: 44,00 USD), mikä merkitsee +105,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Stoke Therapeutics Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Stoke Therapeutics-osaketta: 19 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Stoke Therapeutics-yhtiöltä 32,03 M USD liikevaihtoa ja −3,56 USD osakekohtaista tulosta.

Stoke Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Stoke Therapeutics-osake noteerataan hintaan 20,62 EUR (23,08 USD).

Stoke Therapeutics-osake (STOK) on listattuna 3 pörssissä, muun muassa: NASDAQ (STOK), Frankfurt (0GT.F), München (0GT.MU).

Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.

odotettu liikevaihto Stoke Therapeutics on 32,03 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Stoke Therapeutics on −208,15 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Stoke Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,47. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Stoke Therapeutics-osakkeen arvostusta.

Stoke Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 42,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Stoke Therapeutics-osakkeen arvostuskennuslukuna.

Stoke Therapeutics:n Eulpool-laatuscore on 3/10.

Stoke Therapeutics:n ISIN on US86150R1077. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Stoke Therapeutics:n WKN on A2PLTL. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Stoke Therapeutics:n ticker on STOK. Tämä pörssinoteeraus käytetään Stoke Therapeutics-osakkeiden kauppaan pörssissä.